Melatonin Use During Pregnancy
Based on current evidence, melatonin should be avoided during pregnancy due to insufficient safety data in humans, despite its theoretical benefits and lack of documented serious adverse effects in limited studies.
Current Evidence and Recommendations
The available guidelines do not specifically address melatonin use in pregnancy. None of the major clinical practice guidelines from 2019-2025 covering pregnancy management 1, 2, 3, 4, 5, 6 mention melatonin as either safe or contraindicated during pregnancy. This absence from authoritative guidelines is itself significant.
Safety Profile: What We Know
Human Data is Limited but Reassuring
A 2022 scoping review found that clinical trials using melatonin during pregnancy for various conditions "have not suggested major safety concerns or adverse events" 7. The review noted that approximately 4% of pregnant women use melatonin, yet concluded that "evidence from clinical studies to date suggests that melatonin use during pregnancy and breastfeeding is probably safe in humans" 7.
A 2016 systematic safety review found that short-term melatonin use is safe even in extreme doses, with only mild adverse effects (dizziness, headache, nausea, sleepiness) 8. However, this same review explicitly stated: "Due to a lack of human studies, pregnant and breast-feeding women should not take exogenous melatonin at this moment" 8.
The Animal vs. Human Evidence Gap
Much concern about melatonin in pregnancy stems from animal research 7. However, animal studies have also demonstrated potential neuroprotective benefits for the fetus 9, 10, 11. A 2024 review argued that melatonin's antioxidant properties may protect against common pregnancy complications including preeclampsia, fetal growth retardation, and premature delivery 9.
Clinical Decision-Making Framework
When to Absolutely Avoid
- First trimester: Greatest concern for teratogenicity, though no documented cases exist
- When alternatives exist: Non-pharmacologic sleep interventions should be prioritized
- Lack of clear indication: Melatonin is not FDA-approved for any indication 12
If Considering Use (Shared Decision-Making Required)
The decision requires weighing:
- Severity of maternal sleep disorder and impact on maternal/fetal health
- Failure of behavioral interventions (sleep hygiene, cognitive-behavioral therapy)
- Gestational age (later pregnancy may carry less theoretical risk)
- Patient understanding that this is off-label use without robust human safety data
Dosing Considerations (If Used)
Based on general melatonin literature (not pregnancy-specific):
- Dose: 3-4 mg appears optimal for sleep promotion 13
- Timing: 1-3 hours before desired bedtime, not 30 minutes 14, 13
- Duration: Short-term use only until safety data improves
Critical Caveats
No randomized controlled trials have specifically evaluated melatonin for insomnia during pregnancy 7, 10. The 2016 Cochrane review found zero completed trials examining melatonin for fetal neuroprotection 10.
Melatonin is a dietary supplement in the US, not FDA-regulated as a medication 15, 12. This means:
- Variable purity between preparations
- Unreliable stated doses
- Recommend only USP-verified formulations 15
Theoretical concerns remain:
- Effects on fetal circadian rhythm development
- Potential hormonal effects on reproductive development 15
- Long-term neurodevelopmental outcomes unknown
Practical Recommendation
Prioritize non-pharmacologic interventions first: sleep hygiene, stimulus control, relaxation techniques. If pharmacologic treatment is necessary for severe insomnia affecting maternal health, discuss with the patient that while limited human data suggests probable safety 7, authoritative guidelines recommend avoidance due to insufficient evidence 8.
If melatonin is used after informed consent, use the lowest effective dose (3-4 mg), administer 1-3 hours before bedtime, limit to short-term use, and choose USP-verified preparations. Document the shared decision-making process and rationale for use despite limited safety data.
The conservative approach—avoiding melatonin during pregnancy—remains most defensible until higher-quality human safety studies are completed.